GDF Trap Polypeptide for Ineffective Erythropoiesis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ineffective erythropoiesis, such as those seen in thalassemia, are inadequate as they often fail to increase red blood cell levels and can exacerbate conditions like splenomegaly and iron overload.
Innovation Solution
The use of GDF Traps, which are variant ActRIIB polypeptides with specific amino acid sequences and modifications, to bind to GDF8 and GDF11, thereby modulating erythropoiesis and increasing red blood cell levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If EPO-based treatments are used to increase red blood cell levels, then hemoglobin levels improve, but the treatment fails in patients with ineffective erythropoiesis and may exacerbate conditions like splenomegaly and iron overload
Solution Approach 1:
The patent extracts and neutralizes the specific growth differentiation factor 8 (sGDF8) that is pathologically elevated in thalassemia patients. By removing the excess sGDF8 from the system using antibodies or antigen-binding fragments, the treatment addresses the root cause of ineffective erythropoiesis without relying on EPO-based approaches that have failed in these patients.
Solution Approach 2:
The treatment applies preliminary action by neutralizing sGDF8 before it can continue to inhibit erythropoiesis. The antibody or antigen-binding fragment binds to sGDF8 in advance, preventing its harmful effects on red blood cell production and creating a favorable environment for erythropoietic recovery.
2Quantity of substance
If higher doses of EPO are administered to overcome resistance, then red blood cell production may increase, but the risk of cardiovascular morbidity, tumor growth, and mortality increases
Solution Approach 1:
The patent converts the harmful effect of sGDF8 (which inhibits erythropoiesis) into a beneficial treatment target. By specifically neutralizing sGDF8 rather than attempting to overcome its effects with higher EPO doses, the treatment achieves red blood cell production improvement without the adverse effects associated with high-dose EPO therapy.
Solution Approach 2:
The antibody or antigen-binding fragment serves as an intermediary that specifically targets and neutralizes sGDF8. This intermediary approach allows for precise modulation of the pathological pathway without the broad effects and risks associated with high-dose EPO administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GDF Traps effectively increase red blood cell levels, reduce symptoms associated with ineffective erythropoiesis such as splenomegaly and iron overload, and improve overall patient health and quality of life.
Implementation Method 1
GDF Traps, which are variant ActRIIB polypeptides with specific amino acid sequences and modifications, to bind to GDF8 and GDF11
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods for treating ineffective erythropoiesis in a patient comprising administering to a patient an ActRIIB polypeptide at least 90% identical to the sequence of amino acids 109 of SEQ ID NO. 1 wherein said polypeptide comprises an acidic amino acid at position 79.